Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emraclidine in acute schizophrenia exacerbation
NCT05227703Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of emraclidine in schizophrenia, sponsored by AbbVie Inc.. Started Jul 2022; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05227703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05227703.